Management of endocrine disease: Secondary osteoporosis: pathophysiology and management
- PMID: 25971649
- PMCID: PMC4534332
- DOI: 10.1530/EJE-15-0118
Management of endocrine disease: Secondary osteoporosis: pathophysiology and management
Abstract
Osteoporosis is a skeletal disorder characterized by decreased mass and compromised bone strength predisposing to an increased risk of fractures. Although idiopathic osteoporosis is the most common form of osteoporosis, secondary factors may contribute to the bone loss and increased fracture risk in patients presenting with fragility fractures or osteoporosis. Several medical conditions and medications significantly increase the risk for bone loss and skeletal fragility. This review focuses on some of the common causes of osteoporosis, addressing the underlying mechanisms, diagnostic approach and treatment of low bone mass in the presence of these conditions.
© 2015 European Society of Endocrinology.
Similar articles
-
Drug-induced osteoporosis: mechanisms and clinical implications.Am J Med. 2010 Oct;123(10):877-84. doi: 10.1016/j.amjmed.2010.02.028. Am J Med. 2010. PMID: 20920685 Review.
-
Secondary osteoporosis: pathophysiology & diagnosis.Best Pract Res Clin Endocrinol Metab. 2014 Dec;28(6):911-35. doi: 10.1016/j.beem.2014.07.002. Epub 2014 Jul 18. Best Pract Res Clin Endocrinol Metab. 2014. PMID: 25432361 Review.
-
Drug-induced osteoporosis: beyond glucocorticoids.Curr Rheumatol Rep. 2008 Apr;10(2):102-9. doi: 10.1007/s11926-008-0019-4. Curr Rheumatol Rep. 2008. PMID: 18460264 Review.
-
[Absolute risk for fracture and WHO guideline. Treatment of patients with secondary osteoporosis].Clin Calcium. 2007 Jul;17(7):1106-13. Clin Calcium. 2007. PMID: 17607079 Review. Japanese.
-
Update on medications with adverse skeletal effects.Mayo Clin Proc. 2011 Apr;86(4):338-43; quiz 343. doi: 10.4065/mcp.2010.0636. Epub 2011 Mar 9. Mayo Clin Proc. 2011. PMID: 21389249 Free PMC article. Review.
Cited by
-
The Value of Mandibular Indices on Cone Beam Computed Tomography in Secondary Causes of Low Bone Mass.J Clin Med. 2024 Aug 16;13(16):4854. doi: 10.3390/jcm13164854. J Clin Med. 2024. PMID: 39200996 Free PMC article.
-
Sirt1: An Increasingly Interesting Molecule with a Potential Role in Bone Metabolism and Osteoporosis.Biomolecules. 2024 Aug 8;14(8):970. doi: 10.3390/biom14080970. Biomolecules. 2024. PMID: 39199358 Free PMC article. Review.
-
Celiac Disease: A Forty-Year Analysis in an Italian Referral Center.Nutrients. 2024 Jul 17;16(14):2292. doi: 10.3390/nu16142292. Nutrients. 2024. PMID: 39064734 Free PMC article.
-
Protective role of exercise on breast cancer-related osteoporosis in women undergoing aromatase inhibitors: A narrative review.Bone Rep. 2024 Mar 25;21:101756. doi: 10.1016/j.bonr.2024.101756. eCollection 2024 Jun. Bone Rep. 2024. PMID: 38577250 Free PMC article. Review.
-
Lactobacillus plantarum 45 activates SHP2 through inhibition of oxidative stress to regulate osteoblast and osteoclast differentiation.Aging (Albany NY). 2024 Apr 3;16(7):6334-6347. doi: 10.18632/aging.205708. Epub 2024 Apr 3. Aging (Albany NY). 2024. PMID: 38575308 Free PMC article.
References
-
- Painter SE, Kleerekoper M, Camacho PM. Secondary osteoporosis: a review of the recent evidence. Endocr Pract. 2006;12:436–445. - PubMed
-
- Harper KD, Weber TJ. Secondary osteoporosis. Diagnostic considerations. Endocrinol Metab Clin North Am. 1998;27:325–348. - PubMed
-
- Nih Consensus Development Panel on Osteoporosis Prevention D Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785–795. - PubMed
-
- Panico A, Lupoli GA, Fonderico F, Marciello F, Martinelli A, Assante R, Lupoli G. Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate. Thyroid. 2009;19:437–442. - PubMed
-
- Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments. Nephrol Dial Transplant. 2009;24:1472–1477. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
